Stock Markets June 30, 2026 11:22 AM

Sarepta Shares Rise After FDA Accepts Filings to Convert Two DMD Therapies to Full Approval

Regulatory acceptance follows ESSENCE data, real-world evidence and safety profiles for AMONDYS 45 and VYONDYS 53; action date set for Feb. 28, 2027

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
SRPT

Sarepta Therapeutics saw its stock climb after the FDA accepted supplemental applications to transition two exon-skipping Duchenne muscular dystrophy therapies from accelerated to traditional approval. The company cited confirmatory trial results, real-world evidence and safety data in its submissions; a regulatory decision is targeted for February 28, 2027.

Sarepta Shares Rise After FDA Accepts Filings to Convert Two DMD Therapies to Full Approval
SRPT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The FDA accepted supplemental NDAs for AMONDYS 45 and VYONDYS 53, with a target action date of February 28, 2027.
  • Submissions draw on the Phase 3 ESSENCE study, real-world evidence and safety profiles to support conversion from accelerated to traditional approvals.
  • More than 1,800 patients globally have been treated with Sarepta’s exon-skipping therapies; real-world analyses report delayed need for nighttime ventilation with VYONDYS 53 and slowed lung function decline with AMONDYS 45.
  • Sectors impacted include biotechnology, pharmaceuticals and rare disease treatment markets as regulatory outcomes influence commercial continuity and market access.

Sarepta Therapeutics Inc shares jumped after U.S. regulators accepted supplemental New Drug Applications that seek to convert two Duchenne muscular dystrophy therapies from their accelerated approvals to standard approvals. The FDA has assigned a target action date of February 28, 2027, for the reviews of AMONDYS 45 and VYONDYS 53.

The company’s filings rely on a combination of data sources, according to the submission documents. Those include results from the Phase 3 ESSENCE confirmatory study, real-world evidence gathered from treated patients and established safety profiles for both exon-skipping treatments.

In the ESSENCE trial, which compared casimersen and golodirsen against placebo, the primary endpoint was not met. Still, numerical trends in the data favored the active treatments. By week 96 of the study, analyses showed treatment-related increases in dystrophin expression and signals of reduced decline in a four-step ascend measure across multiple evaluations.

Beyond the trial population, more than 1,800 patients worldwide have received Sarepta’s exon-skipping therapies, including EXONDYS 51, AMONDYS 45 and VYONDYS 53. Real-world observational analyses cited in the applications point to clinically meaningful outcomes: treatment with VYONDYS 53 was associated with a 7.5 year delay in the need for nighttime ventilation, and AMONDYS 45 treatment has been associated with slowing of lung function decline.

Market analysts took note of the FDA acceptance. Mizuho analyst Uy Ear reiterated an Outperform rating and a $31.00 price target for Sarepta Therapeutics. In commentary accompanying the rating, the analyst said: "We view the FDA filing acceptance as positive news, given investor concerns that the failure of the confirmatory Phase 3 ESSENCE trial to achieve statistical significance (although trending positively) could limit the regulatory path forward. We continue to believe the risk of Amondys 45/Vyondys 53 being withdrawn from the market remains low, given the clinical benefits demonstrated with real-world evidence and the ultra-rare nature of the exon 45 and exon 53 amenable DMD patient populations."

The FDA acceptance and the data supporting the submissions frame the immediate regulatory pathway for these therapies. Companies in the rare disease and biotech sectors frequently combine randomized trial results with real-world evidence and long-term safety data when seeking conversion from accelerated to traditional approvals. In this case, regulators will have until the February 28, 2027 target date to render their decisions on AMONDYS 45 and VYONDYS 53.


Contextual note - The filings under review and the ESSENCE study outcomes provide the basis for regulatory evaluation, while real-world outcomes and safety records are cited to support continued access for the treated populations.

Risks

  • The Phase 3 ESSENCE study did not achieve its primary endpoint, which introduces regulatory risk for conversion to traditional approval - this primarily affects the biotechnology and regulatory sectors.
  • Regulators will need to weigh numerical trends and real-world evidence against the lack of statistical significance in the confirmatory trial, creating uncertainty for market access and investor expectations in the pharmaceutical sector.
  • Decisions on these filings could affect commercial availability and the treatment landscape for ultra-rare exon 45 and exon 53 amenable DMD patient populations, with implications for healthcare providers and payers.

More from Stock Markets

Sherwin-Williams Reclaims Ground From April Lows as Citi Sees Full Recovery to $380 Jun 30, 2026 Chip index posts near-historic first-half surge as AI-related demand lifts sector Jun 30, 2026 BMW Cuts Automotive Margin Forecast to 1-3% as Demand Wanes and Geopolitical Shock Bites Jun 30, 2026 S&P Elevates Airbus to A+ Citing Large Cash Buffer and Strong Backlog Execution Jun 30, 2026 Moody's Raises ATS Corporation Rating After Year of Rapid Deleveraging Jun 30, 2026